Development of resistance to ceftazidime-avibactam during infection treatment in blaOXA-244-carrying E. coli through mutations in acrB and PBP2
This study identifies novel mechanisms of CZA resistance in E. coli involving mutations in AcrB and PBP2, independent of carbapenemase production. These findings highlight the importance of monitoring CZA-treated E. coli for the emergence of resistance through these mechanisms and suggest the need for further research to characterize the functional impact of these mutations.